Katherine Frances Lewis

US Patent:

7291589, Nov 6, 2007

Filed:

Oct 7, 2003

Appl. No.:

10/680800

Inventors:

Penny J. Thompson - Snohomish WA, US
Katherine E. Lewis - Lake Forest Park WA, US
Richard M. Garcia - Kirkland WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

A61K 38/00

US Classification:

514 2, 514 12

Abstract:

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.

US Patent:

7592312, Sep 22, 2009

Filed:

Oct 12, 2006

Appl. No.:

11/548805

Inventors:

Penny J. Thompson - Snohomish WA, US
Katherine E. Lewis - Lake Forest Park WA, US
Richard M. Garcia - Kirkland WA, US
Robert R. West - Seattle WA, US
Paul O. Sheppard - Fall City WA, US

Assignee:

Zymogenetics, Inc. - Seattle WA

International Classification:

A61K 38/00

US Classification:

514 12, 530350

Abstract:

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.

US Patent:

7790862, Sep 7, 2010

Filed:

Jun 13, 2007

Appl. No.:

11/762738

Inventors:

Katherine E. Lewis - Lake Forest Park WA, US
Scott R. Presnell - Tacoma WA, US
James W. West - Seattle WA, US
Robert Mabry - Seattle WA, US
Steven D. Levin - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12P 21/08

US Classification:

5303881, 5303873, 5303879, 530351

Abstract:

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

US Patent:

7910703, Mar 22, 2011

Filed:

Apr 28, 2008

Appl. No.:

12/111117

Inventors:

Katherine E. Lewis - Lake Forest Park WA, US
Scott R. Presnell - Tacoma WA, US
Steven D. Levin - Seattle WA, US
Stephen R. Jaspers - Edmonds WA, US
Monica J. Huber - Mill Creek WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12P 21/08

US Classification:

5303873, 5303881, 530809, 530351, 435 7021, 435 697

Abstract:

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

US Patent:

8227579, Jul 24, 2012

Filed:

Aug 27, 2010

Appl. No.:

12/870199

Inventors:

Katherine E. Lewis - Lake Forest Park WA, US
Scott R. Presnell - Tacoma WA, US
James W. West - Seattle WA, US
Robert Mabry - Seattle WA, US
Brent Meengs - Seattle WA, US
Steven D. Levin - Seattle WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

C12P 21/08

US Classification:

5303881, 5303873, 5303879, 530351, 4241331

Abstract:

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

US Patent:

8333968, Dec 18, 2012

Filed:

Feb 22, 2011

Appl. No.:

13/032501

Inventors:

Katherine E. Lewis - Lake Forest Park WA, US
Scott R. Presnell - Tacoma WA, US
Steven D. Levin - Seattle WA, US
Stephen R. Jaspers - Edmonds WA, US
Monica J. Huber - Mill Creek WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

A61K 39/395

US Classification:

4241331, 4241351, 4241361, 4241411, 53038823, 5303881, 530351

Abstract:

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

US Patent:

8496936, Jul 30, 2013

Filed:

Jun 27, 2012

Appl. No.:

13/534019

Inventors:

Katherine E. Lewis - Lake Forest Park WA, US
Scott R. Presnell - Tacoma WA, US
Steven D. Levin - Seattle WA, US
Robert Mabry - Hanover NH, US
Stephen R. Jaspers - Brewster NY, US
Monica J. Huber - Bothell WA, US

Assignee:

ZymoGenetics, Inc. - Seattle WA

International Classification:

A61K 39/00
A61K 39/395

US Classification:

4241361, 4241331, 4241451, 530351, 530809

Abstract:

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

US Patent:

20060142192, Jun 29, 2006

Filed:

Oct 18, 2005

Appl. No.:

11/253200

Inventors:

Zeren Gao - Redmond WA, US
Rolf Kuestner - Bothell WA, US
Mark Appleby - Shoreline WA, US
Katherine Lewis - Lake Forest Park WA, US
Patricia McKernan - Seattle WA, US
Shannon Okada - Seattle WA, US
David Taft - Kirkland WA, US
Joseph Kuijper - Kenmore WA, US
Stephen Jaspers - Edmonds WA, US
Steven Levin - Seattle WA, US

International Classification:

A61K 38/17
C07K 14/715

US Classification:

514012000, 530350000

Abstract:

The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.